-
Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Date of authorisation: 11/01/2008, Revision: 31, Status: Authorised
30 Jan 2025 17:24 GMT
… of the women receiving Abraxane responded to treatment (72 out of 229 … of Abraxane as first-line treatment during the assessment of the medicine.
In … of patients receiving Abraxane and carboplatin responded to treatment compared with 25% …
-
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
28 Jan 2025 00:55 GMT
…
The FDA has approved trastuzumab deruxtecan for the treatment of … FASCO, professor, department of medicine, division of hematology/ … on the DESTINY-Breast04 trial (NCT03734029).3 Notably, that … ; 59.8%), nab-paclitaxel (Abraxane; 24.4%), or paclitaxel ( …
-
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
27 Jan 2025 14:00 GMT
… receiving second-line Gemcitabine-Abraxane chemotherapy (n=7), … U.S. Food and Drug Administration (FDA), to conduct a … U.S. clinical trials investigating Alpha DaRT treatment of the pancreas … Blumenfeld, MD, MPH (Hadassah Medical Center), and Robert Den, …
-
IMM-1-104 Treatment May Improve Responses in Pancreatic Cancer
18 Jan 2025 01:51 GMT
… treatment of IMM-1-104 in combination with modified Gemzar plus Abraxane … to expand the phase 2a trial to include three additional … Chair and Section Chief for Medical Oncology in the Department of … three phase 2a pancreatic cancer trial groups.
Of the seven …
-
LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer
17 Jan 2025 15:23 GMT
… drugs that have the potential to fill an unmet medical … frequent interactions with the FDA, and if relevant criteria … trial is enrolling patients at least 18 years of age with treatment … gemcitabine plus nab-paclitaxel (Abraxane); have an ECOG performance …
-
Metronomic Capecitabine With an Aromatase Inhibitor Demonstrates Safety, Efficacy in Treatment of HR+, HER2– Metastatic Breast Cancer
15 Jan 2025 17:58 GMT
… controlled phase 3 MECCA trial (NCT02767661).1
Endocrine therapy … FDA in 1998 for patients with MBC resistant to paclitaxel (Abraxane … ; Sun Pharmaceutical Industries Europe B.V.) for treatment of MBC … al. US Food and Drug Administration approval overview in …
-
EMA Grants Orphan Medical Product Designation to Elraglusib in Advanced PDAC
11 Jan 2025 12:34 GMT
… EMA) has granted orphan medicinal product designation to elraglusib … phase 2 [Actuate 1801] trial [NCT03678883] of elraglusib in … gemcitabine and nab-paclitaxel (Abraxane).
In part 3B of … receives FDA orphan drug designation for elraglusib for treatment of …
-
Dr Boreham’s Crucible: Can this cancer drug hopeful meet a desperate unmet need?
30 Dec 2024 20:40 GMT
… Monash Institute of Pharmaceutical Services and Peter … and nab-paclitaxel (Abraxane).
Nine patients recorded … drugs for metastatic pancreatic cancer patients, who have not received previous treatment.
Trials … medical practitioner and does not possess a doctorate …
-
Cipla Shares Rise 10% After USFDA Paves Way For Abraxane Drug Launch
31 Oct 2024 05:47 GMT
… the Abraxane generic.
Abraxane is a paclitaxel-based chemotherapy drug used … the launch timeline of Abraxane due to regulatory challenges … in multiple delays for Abraxane’s anticipated launch, prompting … s pipeline visibility as Abraxane remains a key product …
-
FDA Grants Fast Track Designation to IMM-1-104 for Advanced Melanoma
13 Dec 2024 11:10 GMT
… the treatment is undergoing evaluation in a phase 2a clinical trial … Abraxane; Bristol Myers Squibb), or in combination with folfirinox.2
The trial … the European Society for Medical Oncology 2024 congress, IMM … we are pleased with the FDA’s decision to grant [ …
About
© 1995-2025